Compare BZUN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | ENLV |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | China | Israel |
| Employees | 6762 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 149.0M |
| IPO Year | N/A | 2014 |
| Metric | BZUN | ENLV |
|---|---|---|
| Price | $2.52 | $4.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 263.4K | ★ 377.1K |
| Earning Date | 05-20-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.89 | N/A |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $0.43 |
| 52 Week High | $4.88 | $7.64 |
| Indicator | BZUN | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 65.46 |
| Support Level | $2.44 | $0.79 |
| Resistance Level | $2.58 | $7.64 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.04 | 0.36 |
| Stochastic Oscillator | 5.21 | 59.51 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.